Paper

A Phase II Trial of Olaparib Plus Pembrolizumab in Patients with Recurrent Copy-Number High/p53-Abnormal Endometrial Cancer

Clinical Cancer Research · 2026 · Maria M Rubinstein, Jennifer Y Ge, Qin Zhou et al.